Oxford Vacmedix appoints Belgium based Xpress Biologics to carry out the GLP manufacturing of both lead immunotherapy cancer vaccines, to support Phase 1 applications.
Oxford, UK – 8th February 2019
Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today that Xpress Biologics based in Belgium has been appointed to complete GLP (Good Laboratory Practice) manufacturing and testing of both lead immunotherapy cancer vaccines.
Xpress Biologics will focus on GLP manufacturing and scale up before transferring the manufacturing work to another company to manufacture to GMP (Good Manufacturing Practice) standard for use in Phase 1 trials next year. Previous work on manufacturing has been carried out by Changzhou Biotech (CBI) in China, under contract to OVM, and independently by the Structural Genomics Centre (SGC) in Oxford. This work been transferred to Xpress Biologics to inform and accelerate the GLP manufacturing development of OVM’s two lead vaccines, OVM-100 and OVM-200. OVM-100 is an HPV vaccine targeted at cervical cancer, and OVM-200 represents a new type of vaccine utilising survivin to target solid tumours. Both vaccines are being tested as single agents and in combination with other immune-oncology (IO) agents.
Spun out from the University of Oxford, OVM is commercialising the research led by Dr Shisong Jiang and developed in Oxford University’s Department of Oncology. The technology uses the novel, proprietary platform of recombinant overlapping peptides to design and develop therapeutic cancer vaccines and diagnostics with the potential for increased efficacy, lower costs, simpler regulatory pathways and synergy when used in combination with other IO agents.
William Finch, CEO and Director at OVM, said:
“We are very pleased to have such an experienced company as Xpress Biologics involved in this important phase in the development of our cancer vaccines. This work is critical to OVM’s cancer vaccines being progressed to important clinical milestones both to benefit patients and to return significant shareholder value. The manufacturing work done already by CBI and the SGC has proved very helpful and we are very confident that this appointment will optimise the GLP manufacturing and development of our immunotherapy vaccines”.
Marc Daukant, CEO and Director of Xpress Biologics, added:
“We are delighted to have been appointed to complete the next phase of the manufacturing work on Oxford Vacmedix’s two lead immunotherapy cancer vaccines and look forward to a productive and beneficial partnership with the company. We are confident that we can support the continued growth and development of the company.”
For more information or to arrange an interview, please contact:
William Finch, CEO, Oxford Vacmedix
T: +44 (0)1865 742074 | M: +44(0)7769 903711 | E: firstname.lastname@example.org
About Oxford Vacmedix
Oxford Vacmedix UK Ltd, based on the Oxford Science Park, UK, is a bio-pharma company that utilizes the novel proprietary platform technology of recombinant overlapping peptides (ROPs) invented by Dr Shisong Jiang. ROPs have been validated as a technology to stimulate broad and strong T cell immunity therefore forming a good platform for cancer therapeutic vaccines and diagnostics. The company is a spin-out of the University of Oxford and has extensive contacts and collaborations in China through Changzhou Bioscience that is using the ROP platform in both diagnostics and adoptive cell therapy.
For more information, please visit: www.oxfordvacmedix.com/
About Xpress Biologics, Belgium
Xpress Biologics SA is a leading Contract Development and Manufacturing Organisation based in Milmort, Belgium. The company provides a large range of services including the design of expression systems, the development of manufacturing processes, the production of pre-clinical grade material and the transfer of the process to Contract Manufacturing Organizations for the production of GMP grade material. Xpress Biologics has wide experience in producing all types of biologics including recombinant proteins, antibody fragments, conjugated proteins and plasmid DNA for the vaccine, therapeutics and diagnostic markets.
For more information, please visit: http://www.xpress-biologics.com